logo

GBIO

Generation Bio
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Beats Expectation

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About GBIO

Generation Bio Co.

A biotechnology company that develops gene therapies for the treatment of liver and retina diseases

Pharmaceutical
10/21/2016
06/12/2020
NASDAQ Stock Exchange
115
12-31
Common stock
301 Binney Street, Cambridge, Massachusetts 02142
--
Generation Bio Co. was established on October 21, 2016. The company is an innovative genetic medicine company that leverages its proprietary non-viral gene therapy platform to create a new class of gene therapies that provide long-lasting, reusable treatments for millions of patients with rare and endemic diseases. The company's non-viral gene therapy platform integrates high-volume DNA constructs known as closed DNA or ceDNA; the company's cell-targeted lipid nanoparticle delivery system, or ctLNP; and its established, scalable capillar-free manufacturing process. The company is using the company's approach to develop new gene therapies to deliver genetic payloads to a variety of tissues, including a variety of diseases.

Company Financials

EPS

GBIO has released its 2024 Q4 earnings. EPS was reported at -0.32, versus the expected -0.25, missing expectations. The chart below visualizes how GBIO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GBIO has released its 2024 Q4 earnings report, with revenue of 4.19M, reflecting a YoY change of 45.52%, and net profit of -21.38M, showing a YoY change of 39.23%. The Sankey diagram below clearly presents GBIO’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime